KaloBios Pharmaceuticals, Inc. (KBIO) is one of today’s notable stocks in decline, down as much as 67%. The nosedive comes after the company reported top-line data for Phase 2 Study of KB001-A to treat pseudomonas aeruginosa lung infections in cystic fibrosis patients. KaloBios said that while the data from this study showed KB001-A was generally […]
View the full post at: Morning Buzz: KaloBios Pharmaceuticals (KBIO), Netlist Inc. (NLST), Arena Pharmaceuticals (ARNA), Rockwell Medical (RMTI), FireEye (FEYE)